3.97
Cardiff Oncology Inc 주식(CRDF)의 최신 뉴스
New Product Launches: Will They Boost Cardiff Oncology Inc. Stock in 2025Swing Trade Signals - Newser
Is Cardiff Oncology Inc. stock a growth or value playWatchlist Winner Update - Metal.it
Is Cardiff Oncology Inc. a good long term investmentHigh-octane investment gains - PrintWeekIndia
Published on: 2025-07-25 15:19:32 - PrintWeekIndia
What analysts say about Cardiff Oncology Inc. stockExplosive capital appreciation - Autocar Professional
Cardiff Oncology Inc. Stock Analysis and ForecastExplosive trading opportunities - Autocar Professional
What drives Cardiff Oncology Inc. stock priceFast-track wealth growth - jammulinksnews.com
What makes Cardiff Oncology Inc. stock price move sharplyFree Day Trading Recommendations - Newser
Cardiff Oncology: Volatility Afoot With Onvansertib Update Near-Term (NASDAQ:CRDF) - Seeking Alpha
How Cardiff Oncology Inc. stock performs during market volatilityControlled Risk High Reward Plan - Newser
Why Cardiff Oncology Inc. stock attracts strong analyst attentionAlpha Stock Ideas - Newser
Cardiff Oncology (CRDF) Initiated with a Buy at Ladenburg Thalmann & Co. - The Globe and Mail
Cardiff Oncology (NASDAQ:CRDF) Earns Buy Rating from Analysts at LADENBURG THALM/SH SH - Defense World
Brokerages Set Cardiff Oncology, Inc. (NASDAQ:CRDF) Price Target at $11.70 - Defense World
Cardiff Oncology, Inc. (CRDF) Reports 40% Response Rate in mTNBC Trial of Onvansertib + Paclitaxel - MSN
Cardiff Oncology stock initiated with Buy rating at Ladenburg Thalmann By Investing.com - Investing.com Canada
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies - GlobeNewswire
International Business Times - FinancialContent
Cardiff Oncology Up 16%, Insider Buyers Are Up 35% - simplywall.st
While institutions invested in Cardiff Oncology, Inc. (NASDAQ:CRDF) benefited from last week's 16% gain, retail investors stood to gain the most - Yahoo Finance
Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity - Seeking Alpha
Cardiff Oncology Holds Annual Stockholders Meeting 2025 - TipRanks
Jefferies Initiates Coverage on Cardiff Oncology (CRDF) with Hol - GuruFocus
Cardiff Oncology (CRDF) Begins Coverage With Hold Rating from Jefferies | CRDF Stock News - GuruFocus
This MakeMyTrip Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday - Benzinga
Cardiff Oncology stock initiated at Hold by Jefferies on early data concerns - Investing.com
Market Overreaction to Cardiff Oncology's Data Delay Presents a Rare Buying Opportunity - AInvest
Cardiff Oncology (CRDF) Stock Reacts to Delayed Clinical Data Up - GuruFocus
Cardiff Oncology falls after naming new medical chief ahead of key trial readout - MSN
자본화:
|
볼륨(24시간):